Sanoldi Application Scope

Sanoldi (Alfosbuvir) is an innovative antiviral medication combined with daclatasvir hydrochloride to treat genotype 1, 2, 3, and 6 chronic hepatitis C virus (HCV) infections in adults.

sanoldi

Characteristics

Ingredients: Alfosbuvir

Properties:
- A nucleotide prodrug inhibitor of HCV NS5B RNA-dependent RNA polymerase, essential for viral replication.
- Metabolized intracellularly into an active triphosphate form that competes with natural nucleotides
- Leading to premature termination of HCV RNA chain elongation
Packaging Specification: Available as 100 mg tablets

Storage: Store at room temperature (10-30°C) in a dry place, protected from light and moisture
Expiry Date: Typically 24 months from manufacture (check packaging for exact expiration date)
Executive Standard: Complies with Chinese Pharmacopoeia (ChP) and international GMP standards.
Approval Number: Refer to the local regulatory agency (e.g., NMPA approval number for China).
Date of Revision: Refer to the latest prescribing information leaflet for the date of revision.
Manufacturer: Produced by a licensed pharmaceutical company in China

Guidelines for the Use of Sanoldi

Dosage and Administration:
- Recommended dose: 600 mg once daily, combined with Daclatasvir (60 mg once daily) for at least 12 weeks
- It should be taken with or without food, but consistency in administration is advised.

Adverse Reactions:
- Mostly mild to moderate in clinical trials.
- Reported effects include:
  - Elevated triglycerides
  - Increased blood creatine phosphokinase
  - Reduced blood calcium/potassium levels
  - Decreased platelet count (4.3% had Grade ≥3 lab abnormalities)
Contraindications: Hypersensitivity to Alfosbuvir or any excipients
Precautions:
- Monitor liver function and viral load during treatment.
- Not recommended for severe hepatic impairment without medical supervision.
- Avoid abrupt discontinuation unless advised by a physician.

Sanoldi Interactions

Drug Interactions:
- Potential interactions with strong CYP3A4 inducers/inhibitors (may alter Alfosbuvir metabolism)
- No significant interactions reported with Daclatasvir in clinical studies

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.